IGF2BP1 and liver cancer: First, reader antagonism: IGF2BP1 inhibition with BTYNB induces leukemic differentiation in vitro, and new studies are mapping reader dependencies that could support medicinal chemistry campaigns; nanoparticle and EV platforms have already delivered anti-YTHDF1 siRNA in vivo, reshaping myeloid/TAM programs and enhancing therapy in liver cancer models.